Primary study objective
The aim of the study is to increase the percentage of patients without metastases who achieve a complete remission on imaging (MRI and PET) after induction therapy. As a result, the radiation dose can be reduced from 59.4 Gy to 54 Gy in patients under 26 years of age with complete remission.
Secondary study objectives
To evaluate whether nivolumab can be safely used in combination with standard chemotherapy with cisplatin and 5-fluorouracil in children and adults with NPC.
To evaluate whether nivolumab can be safely used in combination with radiochemotherapy in patients who have not responded to induction therapy or have metastases.
